Novartis CAR-T Therapy Drug Recommended by FDA Panel – Zacks.com
|
Novartis CAR–T Therapy Drug Recommended by FDA Panel
Zacks.com Earlier in 2017, Novartis submitted its Biologics License Application (BLA) for CTL019 to the FDA, marking the first submission by Novartis for a CAR–T cell therapy. We remind investors that CTL019 previously received FDA Breakthrough Therapy designation. |
